ACTRN12612000644864尚未招募未知
Management of diarrhoea in patients receiving enteral nutrition by reducing intake of poorly absorbed short-chain carbohydrates (FODMAPs)
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Inpatients requiring enteral nutrition to provide at least 75% estimated nutritional requirements as determined by the assessing dietitian.
排除标准
- •1. Pre-existing diarrhoea
- •2. Enteral nutrition delivered directly into the jejunum
- •3. Patients with co-morbidities that predisposes them to diarrhoea, such as inflammatory bowel disease or previous intestinal resectional surgery
- •4. Patients anticipated to receive enteral nutrition in hospital for less than three days
- •5. Gastrointestinal surgery during current hospital admission
- •6. Patients admitted due to complication of gastrointestinal surgery
- •7. Patients requiring specialty enteral formula/regimen
- •8. Patients with psychiatric illness including anorexia nervosa
研究者
相似试验
已完成
不适用
Improving diarrhoea management in children through the development of rotavirus diarrhoea diagnostic kits and viral diarrhoea awareness to reduce diarrhoea illness and deathRotavirus Group A (RVA) diarrhoeaInfections and InfestationsISRCTN15812702Obafemi Awolowo University186
招募中
1 期
Study on the treatment of diarrhea-predominant irritable bowel syndrome with Xifenghuashi Granules through changes in intestinal floraITMCTR2100004795Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine
招募中
Unknown
Clinical Observation of Patients with Diarrhea-predominant Irritable Bowel Syndrome Treated by Xifeng Huashi Prescription Combined with Low FODMAP DietITMCTR2024000041Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine
进行中（未招募）
1 期
Treatment of Diarrhea-predominant Irritable Bowel Syndrome with LACTEOL 340 mg : a pilot study evaluating safety and efficacyDiarrhea-predominant Irritable Bowel SyndromeMedDRA version: 12.1Level: LLTClassification code 10060845Term: Diarrhea predominant irritable bowel syndromeEUCTR2009-017874-20-FRAXCAN PHARMA SAS60
进行中（未招募）
不适用
Treatment of Diarrhea-predominant Irritable Bowel Syndrome with LACTEOL 340 mg : a pilot study evaluating safety and efficacyDiarrhea-predominant Irritable Bowel SyndromeMedDRA version: 12.1Level: LLTClassification code 10060845Term: Diarrhea predominant irritable bowel syndromeEUCTR2009-017874-20-DEAXCAN PHARMA INC60